Frontiers in Medicine (Aug 2023)

Case report: Allogeneic stem cell transplantation for type B insulin resistance

  • Thomas Ebert,
  • Gerhard Behre,
  • Gerhard Behre,
  • Lorenz Weidhase,
  • Vladan Vucinic,
  • Cornelia Gewert,
  • Cornelia Gewert,
  • Robert K. Semple,
  • Robert K. Semple,
  • Robert K. Semple,
  • Michael Stumvoll,
  • Anke Tönjes

DOI
https://doi.org/10.3389/fmed.2023.1200037
Journal volume & issue
Vol. 10

Abstract

Read online

Type B insulin resistance (TBIR) is a rare, often fulminant form of insulin resistance caused by autoantibodies against the insulin receptor. If left untreated, its mortality is high. Various immunosuppressive regimens have shown efficacy, but treatment effects are variable and time-delayed, and drug-induced complications may arise. We report a patient with TBIR arising as a complication of Wiskott–Aldrich syndrome. Stable remission of TBIR was achieved through allogeneic peripheral blood stem cell transplantation (PBSCT) over a follow-up period of more than 1.5 years. We thus demonstrate that PBSCT can be considered a treatment option in TBIR where conventional immunosuppressive therapy is ineffective or contraindicated.

Keywords